X-ray crystallography and computational docking for the detection and development of protein-ligand interactions

Current Medicinal Chemistry

Volumn 20, Issue 4, 2013, Pages 569-575

  Kershaw, N M ^a   Wright, G S A ^a   Sharma, R ^a   Antonyuk, S V ^a   Strange, R W ^a   Berry, N G ^a   O'Neill, P M ^a   Hasnain, S S ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Amyotrophic lateral sclerosis; Computational chemistry; Fragment based drug discovery; Ligand docking; Superoxide dismutase; X ray crystallography

Indexed keywords

CATECHOLAMINE; COPPER ZINC SUPEROXIDE DISMUTASE; LIGAND; PROTEIN; QUINAZOLINE; THIOREDOXIN RELATED PROTEIN 32; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; PROTEIN INTERACTION; X RAY CRYSTALLOGRAPHY;

EID: 84877775188     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986713804910120     Document Type: Article

References (53)

1. Erlanson, D.A.; Introduction to Fragment-Based Drug Discovery. Top. Curr. Chem., 2012, 317, 1-32.
2. Davies, T.G.; Hyvönen, M. Fragment-Based Drug Discovery and X-Ray Crystallography. Top. Curr. Chem., 2012, 317, 1-222.
3. Kuo, L.C. Fragment Based Drug Design, Volume 493: Tools, Practical Approaches, and Examples (Methods in Enzymology); 1st ed.; Academic Press: New York, 2011.
4. Congreve, M.; Chessari, G.; Tisi, D.; Woodhead, A.J. Recent developments in fragment-based drug discovery. J. Med. Chem., 2008, 51, 3661-3680. (Pubitemid 351956496)
5. Hajduk, P.; Greer J. A decade of fragment-based drug design: strategic advances and lessons learned. Nat. Rev. Drug Discov., 2007, 6, 211-219. (Pubitemid 46344625)
6. Rees, D.C.; Congreve, M.; Murray, C.W.; Carr, R. Fragment-based lead discovery. Nat. Rev. Drug Disc., 2004, 3, 660-672. (Pubitemid 39173507)
7. Erlanson, D.A.; McDowell, R.S.; O'Brien T., Fragment-Based Drug Discovery. J. Med. Chem., 2004, 47, 3463-3482. (Pubitemid 38822007)
8. Hann, M.M.; Leach, A.R.; Harper, G. Molecular complexity and its impact on the probability of finding leads for drug discovery. J. Chem. Inf. Comput. Sci., 2001, 41, 856-864.
9. Fink, T.; Bruggesser, H.; Reymond J.L. Virtual Exploration of the Small-Molecule Chemical Universe below 160 Daltons. Angew. Chem. Int. Ed., 2005, 44, 1504-1508. (Pubitemid 40460043)
10. Fink, T.; Reymond J.L. Virtual Exploration of the Chemical Universe up to 11 Atoms of C, N, O, F:Assembly of 26.4 Million Structures (110.9 Million Stereoisomers) and Analysis for New Ring Systems, Stereochemistry, Physicochemical Properties, Compound Classes, and Drug Discovery. J. Chem. Inf. Model., 2007, 47, 342-353. (Pubitemid 46615939)
11. Cheng, Y.; Judd, T.C.; Bartberger, M.D.; Brown, J.; Chen, K.; Fremeau, Jr., R.T.; Hickman, D.; Hitchcock, S.A.; Jordan, B.; Li, V.; Lopez, P.; Louie, S.W.; Luo, Y.; Michelsen, K.; Nixey, T.; Powers, T.S.; Rattan, C.; Sickmier, E.A.; St. Jean, D.J. Jr.; Wahl, R.C.; Wen, P.H.; Wood S. From Fragment Screening to In Vivo Efficacy: Optimization of a Series of 2-Aminoquinolines as Potent Inhibitors of Beta-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1). J. Med. Chem., 2011, 54, 5836-5857.
12. Barker, J.J.; Barker, O.; Courtney, S.M.; Gardiner, M.; Hesterkamp, T.; Ichihara, O.; Mather, O.; Montalbetti, C.A.; Müller, A.; Varasi, M.; Whittaker, M.; Yarnold C.J. Discovery of a novel Hsp90 inhibitor by fragment linking. Chem. Med. Chem., 2010, 5, 1697-1700.
13. Petros, A.M.; Huth, J.R.; Oost, T.; Park, C.-M.; Ding, H.; Wang, X.; Zhang, H.; Nimmer, P.; Mendoza, R.; Sun, C.; Mack, J.; Walter, K.; Dorwin, S.; Gramling, E.; Ladror, U.; Rosenberg, S.H.; Elmore, S.W.; Fesik, S.W.; Hajduk P.J. Discovery of a potent and selective Bcl-2 inhibitor using SAR by NMR. Bioorg. Med. Chem. Lett., 2010, 20, 6587-6591.
14. Neumann, T.; Junker, H-D.; Schmidt, K.; Sekul, R. SPR-based Fragment Screening: Advantages and Applications. Curr. Top. Med. Chem., 2007, 7, 1630-1642. (Pubitemid 350131018)
15. Murray, C.W.; Blundell, T.L. Structural biology in fragment-based drug design. Curr. Opinion Struct. Biol., 2010, 20, 497-507.
16. Davies, T G.; Tickle, I.J. Fragment Screening Using X-Ray Crystallography. Top. Curr. Chem., 2012, 317, 33-59.
17. Murray, C.W.; Callaghan, O.; Chessari, G.; Cleasby, A.; Congreve, M.; Frederickson, M.; Hartshorn, M.J.; McMenamin, R.; Patel, S.; Wallis, N. Application of fragment screening by X-ray crystallography to betasecretase. J. Med. Chem., 2007, 50, 1116-1123. (Pubitemid 46496312)
18. Antonyuk, S.; Strange, R.W.; Hasnain S.S. Structural discovery of small molecule binding sites in Cu-Zn human superoxide dismutase familial amyotrophic lateral sclerosis mutants provides insights for lead optimization. J. Med. Chem., 2010, 53, 1402-1406.
19. Mitchell, J.D.; Borasio, G.D. Amyotrophic lateral sclerosis. Lancet, 2007, 369, 2031-2041.
20. Traynor, B.J.; Codd, M.B.; Corr, B.; Forde, C.; Frost, E.; Hardiman, O.M. Clinical features of amyotrophic lateral sclerosis according to the El Escorial and Airlie House diagnostic criteria: A population-based study. Arch. Neurol., 2000, 57, 1171-1176. (Pubitemid 30644664)
21. Miller, R.G.; Mitchell, J.D.; Moore, D.H. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database of Syst. Rev., 2012, Mar 14; 3: CD001447.
22. Rosen, D.R.; Siddique, T.; Patterson, D.; Figlewicz, D.A.; Sapp, P.; Hentati, A.; Donaldson, D.; Goto, J.; Regan, J.P.; Deng, H.X.; Rahmani, Z.; Krizus, A.; McKenna-Yasek, D.; Cayabyab, A.; Gaston, S.M.; Berger, R.; Tanzi, R.E.; Halperin, J.J.; Herzfeld, B.; Van Den Bergh, R.; Hung, W.-Y.; Bird, T.; Deng, G.; Mulder, D.W.; Smyth, C.; Laing, N.G.; Soriano, E.; Pericak-Vance, M.A.; Haines, J.; Rouleau, G.A.; Gusella, J.S.; Horvitz, H.R.; Brown, R.H. Jn. Mutations in Cu/Zn superoxide-dismutase gene are associated with familial amyotrophic-lateral-sclerosis. Nature, 1993, 362, 59-62. (Pubitemid 23087289)
23. Deng, H.-X.; Hentati, A.; Tainer, J.A.; Iqbal, Z.; Cayabyab, A.; Hung, W.Y.; Getzoff, E.D.; Hu, P.; Herzfeldt, B.; Roos, R.P.; Warner, C.; Deng, G.; Soriano, E.; Smyth, C.; Parge, H.E.; Ahmed, A.; Roses, A.D.; Hallewell, R.A.; Pericakvance M.A.; Siddique T. Amyotrophic-Lateral-Sclerosis And Structural Defects In Cu,Zn Superoxide-Dismutase. Science, 1993, 261, 1047-1051. (Pubitemid 23300865)
24. Wroe, R.; Ling, W.; Butler, A.; Andersen, P.M.; Powell, J.F.; Al-Chalabi, A. ALSOD: the Amyotrophic Lateral Sclerosis Online Database. Amyotroph. Lateral. Scler., 2008, 9, 249-250.
25. Bosco, D.A.; Morfini, G.; Karabacak, N.M.; Song, Y.; Gros-Louis, F.; Pasinelli, P.; Goolsby, H.; Fontaine, B.A.; Lemay, N.; McKenna-Yasek, D.; Frosch, M.P.; Agar, J.N.; Julien, J.P.; Brady, S.T.; Brown, R.H. Jr. Wild-type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS. Nat. Neurosci., 2010, 13, 1396-1403.
26. Giasson, B.I.; Duda, J.E.; Murray, I.V.; Chen, Q.; Souza, J.M.; Hurtig, H.I.; Ischiropoulos, H.; Trojanowski, J.Q.; Lee, V.M. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science, 2000, 290, 985-989.
27. LaVoie, M.J.; Ostaszewski, B.L.; Weihofen, A.; Schlossmacher, M.G.; Selkoe, D.J. Dopamine covalently modifies and functionally inactivates parkin. Nat. Med., 2005, 11, 1214-1221. (Pubitemid 43093669)
28. Shimizu, T.; Fukuda, H.; Murayama, S.; Izumiyama, N.; Shirasawa, T. Isoaspartate formation at position 23 of amyloid beta peptide enhanced fibril formation and deposited onto senile plaques and vascular amyloids in Alzheimer's disease. J. Neurosci. Res., 2002, 70, 451-461. (Pubitemid 35222382)
29. Yan, S.-D.; Chen, X.; Schmidt, A.-M.; Brett, J.; Godman, G.; Zou, Y.-S.; Scott, C.W.; Caputo, C.; Frappier, T.; Smith, M.A.; Perry, G.; Yen, S.-H.; Stern, D. Glycated tau protein in Alzheimer disease: A mechanism for induction of oxidant stress. Proc. Natl. Acad. Sci. USA, 1994, 91, 7787-7791. (Pubitemid 24238270)
30. Valentine, J.S.; Doucette, P.A.; Zittin Potter, S. Copper-zinc superoxide dismutase and amyotrophic lateral sclerosis. Annu. Rev. Biochem., 2005, 74, 563-593. (Pubitemid 40995518)
31. Getzoff, E.D.; Cabelli, D.E.; Fisher, C.L.; Parge, H.E.; Viezzoli, M.S.; Banci, L.; Hallewell, R.A. Faster superoxide dismutase mutants designed by enhancing electrostatic guidance. Nature, 1992, 358, 347-351.
32. Arnesano, F.; Banci, L.; Bertini, I.; Martinelli, M.; Furukawa, Y.; O. Halloran, T.V. The unusually stable quaternary structure of human Cu,Znsuperoxide dismutase 1 is controlled by both metal occupancy and disulfide status. J. Biol. Chem., 2004, 279, 47998-48003. (Pubitemid 39540952)
33. Doucette, P.A.; Whitson, L.J.; Cao, X.; Schirf, V.; Demeler, B.; Valentine, J.S.; Hansen, J.C.; Hart, P.J. Dissociation of human copper-zinc superoxide dismutase dimers using chaotrope and reductant. Insights into the molecular basis for dimer stability. J. Biol. Chem., 2004, 279, 54558-54566. (Pubitemid 40053198)
34. Lindberg, M.J.; Normark, J.; Holmgren, A.; Oliveberg, M. Folding of human superoxide dismutase: disulfide reduction prevents dimerization and produces marginally stable monomers. Proc. Natl. Acad. Sci. USA, 2004, 101, 15893-15898. (Pubitemid 39507898)
35. Rodriguez, J.A.; Valentine, J.S.; Eggers, D.K.; Roe, J.A.; Tiwari, A.; Brown, R.H. Jr.; Hayward, L.J. Familial amyotrophic lateral sclerosis-Associated mutations decrease the thermal stability of distinctly metallated species of human copper/zinc superoxide dismutase. J. Biol. Chem., 2002, 277, 15932-15937. (Pubitemid 34967874)
36. Strange, R.W.; Antonyuk, S.; Hough, M.A.; Doucette, P.A.; Rodriguez, J.A.; Hart, P.J.; Hayward, L.J.; Valentine, J.S.; Hasnain, S.S. The structure of holo and metal-deficient wild-type human Cu, Zn superoxide dismutase and its relevance to familial amyotrophic lateral sclerosis. J. Mol. Biol., 2003, 328, 877-891. (Pubitemid 36506893)
37. Elam, J.S.; Taylor, A.B.; Strange, R.; Antonyuk, S.; Doucette, P.A.; Rodriguez, J.A.; Hasnain, S.S.; Hayward, L.J.; Valentine, J.S.; Yeates, T.O.; Hart, P.J. Amyloid-like filaments and water-filled nanotubes formed by SOD1 mutant proteins linked to familial ALS. Nat. Struct. Biol., 2003, 10, 461-467. (Pubitemid 36637644)
38. Winkler, D.D.; Prudencio, M.; Karch, C.M.; Borchelt, D.R.; Hart, P.J. In: Protein Misfolding Diseases: Current and Emerging Principles and Therapies; Dobson C.M.; Kelly, J.W.; Ramirez-Alvarado, M. Eds.; John Wiley and Sons Inc: Hoboken, 2010, pp. 381-402.
39. Wang, J.; Xu, G.; Borchelt, D.R. High molecular weight complexes of mutant superoxide dismutase 1: age-dependent and tissue-specific accumulation. Neurobiol. Dis., 2002, 9, 139-148. (Pubitemid 34261210)
40. Kato, S.; Takikawa, M.; Nakashima, K.; Hirano, A.; Cleveland, D.W.; Kusaka, H.; Shibata, N.; Kato, M.; Nakano, I.; Ohama, E. New consensus research on neuropathological aspects of familial amyotrophic lateral sclerosis with superoxide dismutase 1 (SOD1) gene mutations: inclusions containing SOD1 in neurons and astrocytes. Amyotroph. Lateral Scler. Other Motor Neuron Disord., 2000, 1, 163-184.
41. Brown, R.H. SOD1 aggregates in ALS: Cause, correlate or consequence? Nat. Med., 1998, 4, 1362-1364. (Pubitemid 28553453)
42. Valkov, E.; Sharpe, T.; Marsh, M.; Greive, S.; Hyvönen, M. Targeting protein-protein interactions and fragment-based drug discovery. Top. Curr. Chem., 2012, 317, 145-179.
43. Otwinowski, Z.; Minor, W. Processing of X-ray diffraction data collected in oscillation mode. Method Enzymol., 1997, 276, 307-326. (Pubitemid 27085611)
44. Murshudov, G.N.; Vagin, A.A.; Dodson, E.J.; Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D Biol. Crystallogr., 1997, 53, 240-255. (Pubitemid 27235885)
45. Emsley, P.; Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr., 2004, 60, 2126-2132. (Pubitemid 41742764)
46. Hartshorn, M.J.; Verdonk, M.L.; Chessari, G.; Brewerton, S.C.; Mooij, W.T.M.; Mortenson, P.N.; Murray, C.W. Diverse, High-Quality Test Set for the Validation of ProteinLigand Docking Performance J. Med. Chem., 2007, 50, 726-741. (Pubitemid 46332985)
47. DeSimone, R.W.; Currie, K.S.; Mitchell, S.A.; Darrow, J.W.; Pippin, D.A. Privileged structures: applications in drug discovery. Comb. Chem. High Throughput Screening, 2004, 7, 473-494.
48. Nowak, R.J.; Cuny, G.D.; Choi, S.; Lansbury, P.T.; Ray, S.S. Improving binding specificity of pharmacological chaperones that target mutant superoxide dismutase-1 linked to familial amyotrophic lateral sclerosis using computational methods. J. Med. Chem., 2010, 53, 2709-2718.
49. Wright, G.A.S.; Kershaw, N.M.; Strange, R.W.; Antonyuk, S.; Hasnain, S.S. submitted to Nat. Commun. and currently undergoing peer review.
50. Erlanson, D.A. Fragment-based lead discovery: a chemical update. Curr. Opin. Biotechnol., 2006, 17, 643-652. (Pubitemid 44791912)
51. Tuccinardi, T.; Botta, M.; Giordano, A.; Martinelli, A. Protein Kinases: Docking and Homology Modeling Reliability. J. Chem. Inf. Model. 2010, 50, 1432-1441.
52. Job, G.E.; Buchwald, S.L. Copper-Catalyzed Arylation of -Amino Alcohols. Org. Lett., 2002, 4, 3703-3706.
53. Congreve, M.; Carr, R.; Murray, C.; Jhoti, H. A . rule of three. for fragmentbased lead discovery? Drug Discov. Today, 2003, 8, 876-877.